A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study

por Weiden, Peter J., Manning, Raymond, Wolfgang, Curt D., Ryan, J. Michael, Mancione, Linda, Han, Guangyang, Ahmed, Saeed, Mayo, Mallery G.
Publicado 2016

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

por Cross, Anne H., Delgado, Silvia, Habek, Mario, Davydovskaya, Maria, Ward, Brian J., Cree, Bruce A. C., Totolyan, Natalia, Pingili, Ratnakar, Mancione, Linda, Hu, Xixi, Sullivan, Roseanne, Su, Wendy, Zielman, Ronald, Gupta, Ayan Das, Montalban, Xavier, Winthrop, Kevin
Publicado 2022

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

por Cross, Anne H., Delgado, Silvia, Habek, Mario, Davydovskaya, Maria, Ward, Brian J., Cree, Bruce A. C., Totolyan, Natalia, Pingili, Ratnakar, Mancione, Linda, Hu, Xixi, Sullivan, Roseanne, Su, Wendy, Zielman, Ronald, Gupta, Ayan Das, Montalban, Xavier, Winthrop, Kevin
Publicado 2022

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

por Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Das Gupta, Ayan, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, Kappos, Ludwig
Publicado 2022